Neurochemistry · Emotional Wellness

Pioneering the science of human flourishing

Nuvaris Therapeutics develops breakthrough therapies targeting the neurochemical pathways underlying mood, resilience, and emotional health. Two late-stage assets. One clear mission.

Clinical Assets

Phase 3

Lead Program

Patents Granted

380+

Employees

$610M

Cash & Equivalents

2019

Founded

Clinical Pipeline

Two novel therapies. Measurable lives changed.

Our pipeline targets two of the most underserved conditions in neuropsychiatry.

Phase 3 · Pivotal

NVR-401

ElyvaMood™

Major Depressive Disorder (MDD)

A first-in-class selective serotonin allosteric modulator (SSAM). RADIANT-3 trial fully enrolled (n=842). Primary readout expected Q3 2026.

Phase 2 · Proof of Concept

NVR-205

SeroGuard™

Generalized Anxiety Disorder (GAD)

A neuroimmune resilience modulator targeting the gut-brain serotonin axis. Induces durable anxiolytic response in preclinical and Phase 1 data.

Preclinical

NVR-118

Discovery

Treatment-Resistant Depression (TRD)

Next-generation asset targeting neuroplasticity via BDNF pathway enhancement. IND submission anticipated H1 2027.

About Nuvaris

Science-first. Patient-led. Always.

Founded in 2019 by neuroscientists from MIT and UCSF, Nuvaris emerged from a simple observation: the neurochemical basis of emotional wellness had been underinvested for a generation. We are changing that.

Headquartered in Cambridge, MA with research operations in South San Francisco, our 380-person team combines deep neuroscience expertise with disciplined clinical development.

Rigor

Highest standards of scientific integrity.

Transparency

Open communication with all stakeholders.

Access

Therapies should reach every patient.

Urgency

Millions wait. We do not delay.

Leadership Team

Experienced operators. Driven scientists.

Margaret Lowe, Ph.D.

CEO & Co-Founder

Raj Krishnamurthy, M.D.

Chief Medical Officer

Sophia Park, Ph.D.

CSO & Co-Founder

Daniel Whitmore

Chief Financial Officer

Newsroom

Latest news & press releases

Clinical Update

Nuvaris Announces Completion of Enrollment in RADIANT-3 Phase 3 Trial

842 patients enrolled across 68 clinical sites. Primary endpoint data expected Q3 2026.

Financial

Q4 and Full Year 2025 Financial Results

Cash position of $610M provides runway through multiple clinical readouts.

Partnerships

Collaboration with Mass General to Study SeroGuard in PTSD

Expanding clinical evidence for neuroimmune resilience modulation in trauma.

Careers

Join us. The work matters.

We're building a team of exceptional scientists and operators who want their work to have direct patient impact.

Clinical Trial Manager — RADIANT-3

Cambridge, MA · Hybrid · Full-time

Clinical

Principal Scientist, Neuroimmunology

South San Francisco, CA · On-site

Research

Regulatory Affairs Manager

Remote · US · Full-time

Regulatory

Biostatistician II

Remote · US · Full-time

Biometrics

Investor Relations

NUVR · NASDAQ

Committed to transparent, timely communication with our shareholders.

Share Price

$48.32

Market Cap

$3.2B

Cash Position